Determinants of Surgical Approach and Survival Among Women with Endometrial Carcinoma.


Journal

Journal of minimally invasive gynecology
ISSN: 1553-4669
Titre abrégé: J Minim Invasive Gynecol
Pays: United States
ID NLM: 101235322

Informations de publication

Date de publication:
02 2022
Historique:
received: 28 05 2021
revised: 26 07 2021
accepted: 29 07 2021
pubmed: 5 8 2021
medline: 29 3 2022
entrez: 4 8 2021
Statut: ppublish

Résumé

To investigate determinants of surgical approach among women with endometrial carcinoma (EC) and associations between surgical approach and overall survival (OS). Retrospective cohort. The National Cancer Database, 2010 to 2015. A total of 140 470 patients with histologically confirmed EC who underwent hysterectomy. Patients were grouped according to surgical approach. A total of 140 470 patients with EC were included. Robotic-assisted laparoscopy (RAL) was the most common surgical approach (48.8%), followed by laparotomy (33.6%) and traditional laparoscopy (17.6%). Use of RAL increased over the study period, and the percentages of cases managed by laparotomy decreased. Older women, those with insurance, residing in ZIP codes with lower proportions of individuals who did not graduate from high school, and those treated at noncommunity cancer programs were less likely to undergo laparotomy than RAL, and non-white women, those diagnosed with high-grade histology, and those with advanced-stage EC were more likely to undergo laparotomy than RAL. Compared with RAL, all other surgical approaches were associated with worse OS (laparotomy: hazard ratio 1.21; 95% confidence interval, 1.18-1.25; traditional laparoscopy: hazard ratio 1.06; 95% confidence interval, 1.02-1.09). Significant effect modification of the surgical approach and OS relationship according to age, race, histology, stage, and adjuvant treatment was observed. RAL increased in frequency over the study period and was associated with improved OS, supporting the continued use of RAL for EC management.

Identifiants

pubmed: 34348183
pii: S1553-4650(21)00358-7
doi: 10.1016/j.jmig.2021.07.018
pmc: PMC8803987
mid: NIHMS1736782
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

219-230

Subventions

Organisme : NCI NIH HHS
ID : K01 CA218457
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 AAGL. Published by Elsevier Inc. All rights reserved.

Références

Eur J Surg Oncol. 2017 Jun;43(6):994-1002
pubmed: 27546015
J Clin Oncol. 2012 Mar 1;30(7):695-700
pubmed: 22291074
Ann Surg Oncol. 2016 Oct;23(11):3744-3748
pubmed: 27172774
Int J Med Robot. 2017 Dec;13(4):
pubmed: 28762635
Ann Surg Oncol. 2017 Jun;24(6):1677-1687
pubmed: 28074326
Obstet Gynecol. 2012 Apr;119(4):717-24
pubmed: 22433334
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Ann Surg Oncol. 2008 Mar;15(3):683-90
pubmed: 18183467
J Clin Oncol. 2009 Nov 10;27(32):5331-6
pubmed: 19805679
Gynecol Oncol. 2014 Jun;133(3):556-62
pubmed: 24708920
J Clin Oncol. 2016 Apr 1;34(10):1087-96
pubmed: 26834057
Gynecol Oncol. 2020 Feb;156(2):451-458
pubmed: 31780236
Gynecol Oncol. 2013 Apr;129(1):49-53
pubmed: 23262377
Gynecol Oncol. 2015 Nov;139(2):300-5
pubmed: 26363212
J Minim Invasive Gynecol. 2009 May-Jun;16(3):291-301
pubmed: 19423061
Gynecol Oncol. 2011 Sep;122(3):604-7
pubmed: 21658752
Gynecol Oncol. 2016 May;141(2):218-224
pubmed: 26896826
J Surg Oncol. 2016 Dec;114(7):884-887
pubmed: 27566529
JAMA. 2017 Mar 28;317(12):1224-1233
pubmed: 28350928
JAMA Surg. 2013 Dec;148(12):1116-22
pubmed: 24089326
Int J Gynecol Cancer. 2017 Sep;27(7):1508-1516
pubmed: 29470186
Gynecol Oncol. 2020 May;157(2):482-486
pubmed: 32008793
JAMA Surg. 2019 Jun 1;154(6):530-538
pubmed: 30810740
Curr Opin Obstet Gynecol. 2016 Aug;28(4):304-10
pubmed: 27362711
Cochrane Database Syst Rev. 2019 Apr 15;4:CD011422
pubmed: 30985921
J Clin Oncol. 2012 Mar 10;30(8):783-91
pubmed: 22291073
Am J Obstet Gynecol. 2015 Jul;213(1):49.e1-49.e8
pubmed: 25644437
J Am Coll Surg. 2012 Apr;214(4):539-47; discussion 547-9
pubmed: 22321524

Auteurs

Kristin Bixel (K)

Division of Gynecologic Oncology (Drs. Bixel and Barrington). Electronic address: Kristin.bixel@osumc.edu.

David A Barrington (DA)

Division of Gynecologic Oncology (Drs. Bixel and Barrington).

Monica H Vetter (MH)

Division of Gynecologic Oncology, Baptist Health Medicine Group, Lexington, Kentucky (Dr. Vetter).

Adrian A Suarez (AA)

Division of Surgical Pathology (Dr. Suarez), College of Medicine.

Ashley S Felix (AS)

Division of Epidemiology, College of Public Health (Dr. Felix), The Ohio State University, Columbus, Ohio.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH